-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$18.00158.25% Upside
Perspective Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Perspective Therapeutics, Inc.?
Perspective Therapeutics, Inc. has been rated by research analysts at UBS, Oppenheimer, Truist Financial, Bank of America Securities, RBC Capital in the past 90 days.